Cidara Therapeutics Inc (CDTX):企業の財務・戦略的SWOT分析

◆英語タイトル:Cidara Therapeutics Inc (CDTX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH2305574FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥68,400見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥102,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cidara Therapeutics Inc (Cidara), formerly K2 Therapeutics Inc is a biotechnology company that discovers, develops and commercializes novel anti-infectives including immunotherapies. The company’s pipeline products include CD101 for treatment of invasive fungal disease; and CD377 for treating influenza. The company is investigation RSV AVC program for treatment of respiratory syncytial virus (RSV); HIV AVC for human immunodeficiency viruses (HIV); CoV AVC for pan corona virus. Cidara proprietary Cloudbreak, an antiviral platform to the fight against life-threatening infectious disease that provides potent antiviral activity and immune system engagement in a single molecule. The company works in collaboration with Mundipharma International Ltd to develop and commercialize rezafungin for the treatment and prevention of invasive fungal disease. Cidara is headquartered in San Diego, California, the US.

Cidara Therapeutics Inc Key Recent Developments

Apr 07,2021: Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
Apr 05,2021: Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
Apr 01,2021: Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 03,2021: Cidara Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
Feb 25,2021: Cidara Therapeutics provides corporate update and reports fourth quarter and full year 2020 financial results

This comprehensive SWOT profile of Cidara Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Cidara Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Cidara Therapeutics Inc – Key Information
Cidara Therapeutics Inc – Overview
Cidara Therapeutics Inc – Key Employees
Cidara Therapeutics Inc – Key Employee Biographies
Cidara Therapeutics Inc – Key Operational Heads
Cidara Therapeutics Inc – Major Products and Services
Cidara Therapeutics Inc – History
Cidara Therapeutics Inc – Company Statement
Cidara Therapeutics Inc – Locations And Subsidiaries
Cidara Therapeutics Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Cidara Therapeutics Inc – Business Description
Cidara Therapeutics Inc – Corporate Strategy
Cidara Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Cidara Therapeutics Inc – Strengths
Cidara Therapeutics Inc – Weaknesses
Cidara Therapeutics Inc – Opportunities
Cidara Therapeutics Inc – Threats
Cidara Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Cidara Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Cidara Therapeutics Inc, Key Information
Cidara Therapeutics Inc, Key Ratios
Cidara Therapeutics Inc, Share Data
Cidara Therapeutics Inc, Major Products and Services
Cidara Therapeutics Inc, History
Cidara Therapeutics Inc, Key Employees
Cidara Therapeutics Inc, Key Employee Biographies
Cidara Therapeutics Inc, Key Operational Heads
Cidara Therapeutics Inc, Other Locations
Cidara Therapeutics Inc, Subsidiaries
Cidara Therapeutics Inc, Key Competitors
Cidara Therapeutics Inc, SWOT Analysis
Cidara Therapeutics Inc, Ratios based on current share price
Cidara Therapeutics Inc, Annual Ratios
Cidara Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Cidara Therapeutics Inc (CDTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pilot Energy Ltd (PGY):企業の財務・戦略的SWOT分析
    Summary Pilot Energy Ltd (Pilot), formerly known as Rampart Energy Ltd, is an oil and gas exploration and production company. The company acquires, explores and develops conventional oil and gas assets in Australia. Its projects include Australia EP416 and EP480, Australia WA-481-P, and Australia EP …
  • Neenah Inc:企業の戦略・SWOT・財務情報
    Neenah Inc - Strategy, SWOT and Corporate Finance Report Summary Neenah Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Orix Corporation:企業の戦略・SWOT・財務分析
    Orix Corporation - Strategy, SWOT and Corporate Finance Report Summary Orix Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Ichor Holdings Ltd (ICHR):企業の財務・戦略的SWOT分析
    Ichor Holdings Ltd (ICHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Solo Oil plc (SOLO):企業の財務・戦略的SWOT分析
    Summary Solo Oil Plc (Solo Oil), formerly Immersion Technologies International Plc, is an oil and gas exploration and production company that acquires, explores, develops and produces oil and gas resource development and production assets. The company's non operated oil and gas assets portfolio incl …
  • Mitsubishi Chemical Holdings Corporation:戦略・SWOT・企業財務分析
    Mitsubishi Chemical Holdings Corporation - Strategy, SWOT and Corporate Finance Report Summary Mitsubishi Chemical Holdings Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Texas Instruments Incorporated:企業の戦略・SWOT・財務情報
    Texas Instruments Incorporated - Strategy, SWOT and Corporate Finance Report Summary Texas Instruments Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • CollPlant Ltd (CLGN):医療機器:M&Aディール及び事業提携情報
    Summary CollPlant Holdings Ltd (CollPlant) is a regenerative medicine company that carries out development and commercialization of tissue repair products. The company offers orthobiologics, wound care, and pipeline products. Its orthobiologics products include VergenixSTR and VergenixBVF. CollPlant …
  • BioVendor – Laboratorni Medicina as-製薬・医療分野:企業M&A・提携分析
    Summary BioVendor - Laboratorni Medicina as (BioVendor) is a developer and manufacturer of immunoassays, recombinant protiens, antibodies and endotoxin-removal products. The company’s products include immunoassays, proteins, antibodies, endotoxin removal products, endotoxin detection products, immun …
  • BNC Bancorp:企業のM&A・事業提携・投資動向
    BNC Bancorp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BNC Bancorp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Epcor Utilities Inc:発電所・企業SWOT分析
    Epcor Utilities Inc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Megapharm Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Megapharm Ltd (Megapharm) is a biotechnology company that offers marketing of pharmaceutical products for international companies. The company markets products in therapeutic areas such as central nervous system, dermatology, gastroenterology, urology, respiratory and allergy, oncology, rheu …
  • Cardiovascular Systems Inc (CSII):製品パイプライン分析
    Summary Cardiovascular Systems Inc (CSI) is a medical device company that develops and commercializes products for treating peripheral and coronary vascular disease. The company offers products such as peripheral orbital atherectomy system, coronary orbital atherectomy system, crowns, and accessorie …
  • New Image Group Ltd:企業の戦略的SWOT分析
    New Image Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Shin Kong Financial Holding Co Ltd (2888):企業の財務・戦略的SWOT分析
    Shin Kong Financial Holding Co Ltd (2888) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Troy Resources Limited:企業の戦略・SWOT・財務情報
    Troy Resources Limited - Strategy, SWOT and Corporate Finance Report Summary Troy Resources Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • OmniGuide Inc:医療機器:M&Aディール及び事業提携情報
    Summary OmniGuide Inc (OmniGuide) is a medical device company that offers microsurgery, laparoscopy, and robotic assisted surgery products. The company’s products comprise GYN systems, ENT systems, OTO systems, line of sight systems, robotic surgical products and others. It also offers gynecology su …
  • Nordic Nanovector ASA (NANO):企業の財務・戦略的SWOT分析
    Summary Nordic Nanovector ASA (Nordic Nanovector), formerly Nordic Nanovector AS is a developer and commercializer of antibody radionuclide conjugates for the treatment of hematological cancers. The company’s lead product candidate includes Betalutin, an antibody radionuclide conjugate developed for …
  • SAE Towers Holdings LLC:企業の戦略的SWOT分析
    SAE Towers Holdings LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Hyundai Heavy Industries Co Ltd (009540):電力:M&Aディール及び事業提携情報
    Summary Hyundai Heavy Industries Co Ltd (HHI) is one of the leading shipbuilding companies in the world. HHI manufactures VLCCs, containerships, P/C ships, LNG carriers, and warships. Its offering also includes combined cycle power plant, thermal power plant, oil and gas processing plant, LNG plant, …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆